VISTA, Calif., Aug. 13, 2015 (GLOBE NEWSWIRE) — SeaSpine Holdings Corporation (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported its financial results for the second quarter ended June 30, 2015.
Recent Highlights
- Revenue totaled $33.5 million in the second quarter of 2015, a 6% decrease vs. the second quarter of 2014
- Orthobiologics revenue totaled $17.0 million, a 1% increase vs. the second quarter of 2014
- Spinal Fusion Hardware revenue totaled $16.5 million, a 13% decrease vs. the second quarter of 2014
- Completed tax-free spinoff from Integra LifeSciences Holdings Corporation (NASDAQ:IART) on July 1, 2015, capitalized with $47.0 million in cash
- Launched the Ventura™ NanoMetalene® Interbody Device for use in transforaminal lumbar interbody fusion (TLIF) procedures, the latest such NanoMetalene coated interbody device in the SeaSpine portfolio
- Strengthened leadership team through the addition of two executives with deep experience in spine and the medical technology industry:
- Tyler Lipschultz, Vice President, Orthobiologics and Business Development
- Laetitia Cousin, Vice President, Regulatory, Clinical and Quality Assurance
“Following our successful spin-off from Integra LifeSciences last month, we are excited to move forward with our plans to reinvigorate SeaSpine as an independent public company,” said Keith Valentine, President and Chief Executive Officer. “We are now well positioned financially to make targeted investments that leverage our existing platform of orthobiologics and spinal implants to drive future growth. We are bringing together a highly qualified team of professionals that is committed to new and next-generation product innovation and generation of clinical data, as well as expanding our distribution opportunity. I am excited by our robust pipeline of a dozen new products that we anticipate delivering over the next 24 months and the opportunity to significantly expand relationships with distributors worldwide.”
Second Quarter 2015 Financial Results
Financial results for the second quarter of 2015 are reported using the same carve out basis of accounting that was used for reporting SeaSpine’s financial results in the Form 10 Registration Statement, as amended, filed with the Securities and Exchange Commission.
Revenue for the second quarter decreased 6% to $33.5 million from $35.8 million during the same period of the prior year. Revenue from Orthobiologics was $17.0 million, reflecting growth of 1%, and revenue from Spinal Fusion Hardware was $16.5 million, reflecting a decline of 13%. This decline was primarily attributable to continued pricing pressure, decreased demand for the Company’s existing products, and delays in new product launches. Changes in foreign currency exchange rates reduced reported revenues by $0.3 million in the second quarter of 2015 compared to the prior year period.
Gross profit for the second quarter of 2015 was 56.6%, a slight decrease compared to the same period in 2014. Operating expenses for the second quarter of 2015 increased $9.5 million to $35.0 million, compared to $25.6 million for the same period of the prior year. SG&A expenses increased $9.4 million to $31.7 million for the second quarter of 2015 compared to $22.2 million for the same period of the prior year. This increase was primarily attributable to $9.8 million of spinoff related charges, slightly offset by lower depreciation on instruments sets and lower commission expense.
R&D expenses were relatively flat at $2.0 million for the second quarter of 2015.
Effective income tax rates were (9.6)% and (7.8)% for the second quarter of 2015 and 2014, respectively. The Company reported income tax expense for both periods, despite the reported losses before income taxes in those periods, because the Company’s legal entity structure did not permit the offset of taxable losses generated by certain U.S. subsidiaries against the taxable income generated by another of the Company’s U.S. subsidiaries. In the third quarter of 2015, the Company expects to make an election that will enable all of its subsidiaries to file a joint U.S. consolidated federal income tax return, such that taxable income and losses from all of its U.S. subsidiaries will be included in a single return.
Net loss for the three months ended June 30, 2015 was $17.7 million, compared with net loss of $5.4 million for the three months ended June 30, 2014. Pro forma loss per share, calculated based on the approximately 11.0 million shares of SeaSpine common stock that were distributed to Integra shareholders on July 1, 2015, was ($1.60) for the second quarter of 2015, compared to ($0.49) for the second quarter of 2014.
On July 1, 2015, SeaSpine completed its tax-free spinoff from Integra and was capitalized with $47.0 million in cash and no debt.
About SeaSpine Holdings Corporation
SeaSpine is a global medical technology company focused on the design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. SeaSpine has a comprehensive portfolio of orthobiologics and spinal fusion hardware solutions to meet the varying combinations of products that neurosurgeons and orthopedic spine surgeons need to perform fusion procedures on the lumbar, thoracic and cervical spine. SeaSpine’s orthobiologics products consist of a broad range of advanced and traditional bone graft substitutes that are designed to improve bone fusion rates following a wide range of orthopedic surgeries, including spine, hip, and extremities procedures. SeaSpine’s spinal fusion hardware portfolio consists of an extensive line of products to facilitate spinal fusion in minimally invasive surgery (MIS), complex spine, deformity and degenerative procedures. Expertise in both orthobiologic sciences and spinal fusion hardware product development allows SeaSpine to offer its surgeon customers a differentiated portfolio and a complete solution to meet their fusion requirements. SeaSpine currently markets its products through a network of independent sales agents in the United States and through stocking distributors in over 30 countries worldwide. Read more about SeaSpine at the company’s website, www.seaspine.com.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and reflects the Company’s judgment as of the date of this release. Such forward-looking statements include 2015 revenue guidance, statements regarding SeaSpine’s expected future new product launches, and expectations for future operating costs and expenses. Actual results may differ materially from predicted or expected results. Such risks and uncertainties include, but are not limited to: actions by governmental and regulatory authorities; delays, costs and difficulties related to the spin-off and the operation as a separate, publicly traded company following the spin-off; general economic and political conditions globally and in the markets in which SeaSpine does business; and other factors identified under the heading “Risk Factors” of SeaSpine’s Form 10 Registration Statement, as amended, filed with the Securities and Exchange Commission. These forward-looking statements are made only as the date thereof, and, except as required by law, SeaSpine undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.
– See More